Results 1 to 10 of about 36,696 (303)

Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs [PDF]

Journal of HerbMed Pharmacology, 2018
Introduction: Sulfonylurea antidiabetics are insulin secretogogues useful in the treatment of type 2 diabetic patients. The probability of adverse drug interactions is high in patients taking sulfonylureas and other drugs including herbal medicines.
Naina Mohamed Pakkir Maideen, Rajkapoor Balasubramaniam   +1 more
doaj   +4 more sources

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +3 more sources

Sulfonylurea action re‐revisited [PDF]

Journal of Diabetes Investigation, 2010
Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)‐sensitive K+ (KATP) channels in pancreatic β‐cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (cAMP‐GEFII) to Rap1 signaling, which promotes insulin ...
Seino, Susumu, Chang-Liang Zhang, Shibasaki, Tadao   +2 more
openaire   +3 more sources

The impact of sulfonylureas on diverse ion channels: an alternative explanation for the antidiabetic actions [PDF]

Frontiers in Cell and Developmental Biology
The oral hypoglycemic drug sulfonylureas exhibit substantial therapeutic benefits for millions of patients with type 2 diabetes mellitus (T2DM), although with common adverse effects, such as hypoglycemia.
Xian-Tao Li, Meng-Ze Yun
doaj   +2 more sources

Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort Study

Frontiers in Medicine, 2022
ObjectiveTo investigate the association of concurrent use of oral anticoagulants (OACs) and sulfonylureas and the risk of hypoglycemia in individuals with type 2 diabetes mellitus (T2DM).Research Design and MethodsA retrospective cohort study was ...
Hassan Alwafi, Hassan Alwafi, Ian C. K. Wong, Ian C. K. Wong, Ian C. K. Wong, Ian C. K. Wong, Ian C. K. Wong, Abdallah Y. Naser, Amitava Banerjee, Amitava Banerjee, Amitava Banerjee, Pajaree Mongkhon, Pajaree Mongkhon, Cate Whittlesea, Alaa Alsharif, Li Wei, Li Wei, Li Wei   +17 more
doaj   +1 more source

Pretreatment of Sulfonylureas Reducing Perihematomal Edema in Diabetic Patients With Basal Ganglia Hemorrhage: A Retrospective Case-Control Study

Frontiers in Neurology, 2021
Background: The sulfonylurea receptor 1–transient receptor potential melastatin 4 (SUR1–TRPM4) channel is a target key mediator of brain edema. Sulfonylureas (SFUs) are blockers of the SUR1–TRPM4 channel.
Zhang Jingjing, Zhao Jingjing, Hui Bo, Wang Le, Wei Jingya, Wei Dong, Yang Fang, Jiang Wen   +7 more
doaj   +1 more source

Adding Sodium–Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Endocrinology, 2021
BackgroundHypoglycemia is an important event that could be related to increased mortality in patients with diabetes. The risk of hypoglycemia is not clearly illustrated to increase when Sodiumglucose co-transporter 2 (SGLT-2) inhibitors are used ...
Meng Jiang, Qiaoshu Liu, Tiejian Jiang, Paul Nizigiyimana, Minxiang Lei   +4 more
doaj   +1 more source

Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study

Frontiers in Medicine, 2022
ObjectiveDiabetes mellitus (DM) is associated with immune dysregulation, while sulfonylureas or biguanides have been linked to anti-inflammatory mechanisms.
Yu-Jih Su, Yu-Jih Su, Jing-Yang Huang, Jing-Yang Huang, Cong-Qiu Chu, James Cheng-Chung Wei, James Cheng-Chung Wei, James Cheng-Chung Wei   +7 more
doaj   +1 more source

Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone

Frontiers in Pharmacology, 2021
Periodontitis is one of the most prevalent oral inflammatory diseases leading to teeth loss and oral health problems in adults. Periodontitis mainly affects periodontal tissue by affecting the host immune system and bone homeostasis.
Luxi Yang, Qing Ge, Zhitong Ye, Lijing Wang, Lijing Wang, Liping Wang, Mubarak Ahmed Mashrah, Janak L. Pathak   +7 more
doaj   +1 more source

Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register

Сахарный диабет, 2022
Background: Sulfonylureas (SU) are often used for second and third line type 2 diabetes mellitus (T2DM) therapy. Currently, there are no unified recommendations governing the choice of drugs for the second line therapy.
I. V. Misnikova, Yu. A. Kovaleva, V. A. Gubkina, A. V. Dreval   +3 more
doaj   +1 more source